UNC-sponsored COMBAT HBV trial posts results after completion in DRC
A feasibility study testing tenofovir plus birth-dose vaccine to curb mother-to-child hepatitis B transmission reports results after wrapping up enrollment of 315 participants.
One trial update this week involves a University of North Carolina at Chapel Hill-sponsored study conducted in the Democratic Republic of Congo, with results posted after the study's completion.
- "COMBAT HBV Feasibility Trial" (NCT05705427), a Phase 4, randomized, double-blind, placebo-controlled study, tested whether giving HBV-infected pregnant women tenofovir or placebo starting at 28-32 weeks' gestation and continuing through 4 weeks postpartum1 could help prevent mother-to-child transmission of hepatitis B in the Democratic Republic of Congo. The study completed on 2025-11-25 with 315 participants enrolled, and infants in both the tenofovir and placebo arms received a birth-dose hepatitis B vaccine1. Results were first posted on 2026-11-16.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.